Asia Top 20 Survey Fastest 50 Bioscience Companies in Asia

� BioSpectrum | www.BioSpectrumAsia.com | A CyberMedia Publication

Fastest 50

Rank Company Country Revenue CY 2012

Revenue CY 2011

Revenue CY 2010

Revenue CY 2009

Revenue CY 2008

% Growth over 2011

1 Huapont-Nutrichem (formerly Chongqing Huapont Pharm) China 618.30 105.52 80.43 79.68 84.24 485.96

2 Bionomics Australia 13.80 4.12 4.04 3.20 3.03 234.95

3 Taiwan Liposome Company Taiwan 7.22 2.35 - - - 207.68

4 Cordlife Singapore 9.56 3.51 23.44 19.42 13.13 172.36

5 Living Cell Technologies Australia/New Zealand 6.29 2.47 2.26 - - 154.48

6 Apeloa Company China 556.82 245.52 - 196.92 - 126.79

7 Acrux Australia 11.22 5.15 135.22 1.36 2.72 117.86

8 Nanosonics Australia 12.68 5.98 1.73 0.89 1.33 112.06

9 Universal Biosensors Australia 30.70 15.15 16.85 17.46 2.48 102.64

10 Guilin Layn Natural Ingredients* China 38.70 19.81 60.25 16.64 - 95.36

11 Pharmaxis Australia 2.16 1.13 5.06 3.81 8.04 90.95

12 Genetic Technologies Australia 3.65 2.06 14.24 8.29 9.25 77.20

13 Nantong Jinghua Pharmaceutical China 106.43 60.08 40.52 37.96 34.37 77.15

14 Medy-Tox South Korea 32.50 19.53 18.45 13.75 8.08 66.41

15 Beijing SL Pharmaceutical China 161.20 99.65 67.62 52.90 - 61.77

16 Austofix Australia 2.00 1.24 - - - 61.23

17 Cyclopharm Australia 11.10 7.11 8.80 10.77 7.76 56.12

18 Allied Overseas (Quality HealthCare Asia) China 27.17 17.43 13.00 - - 55.85

19 Guangzhou Pharmaceutical China 1316.66 870.34 650.38 556.40 517.22 51.28

20 Allied Biotech Taiwan 16.10 10.67 - - - 50.83

21 Concord Medical Services China 107.54 72.02 57.53 42.27 32.85 49.31

22 Hua Han Bio-Pharmaceutical China 224.25 150.49 104.07 134.52 30.99 49.01

23 Vita Life Sciences Australia 37.23 25.15 - - - 48.04

24 Tianjin Lisheng Pharmaceutical China 178.91 122.18 109.01 87.17 86.70 46.43

25 OK Biotech Taiwan 22.00 15.19 - - - 44.84

* Q4 Revenue extrapolated/estimated due to non-availability of data (Revenue in million $)

» These 50 companies contributed $31 billion to the $86.87 billion total revenue of publicly listed companies

» Asia’s leading company Sinopharm made it to the list at No. 46, clocking a growth of over 30 percent

» Australia and New Zealand had 15 companies in the list, same number as China. India made it to the list with 10 companies

Asia’s Fastest

Fastest 50 Bioscience Companies in Asia - 2012 (By % Growth)

A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum �

Asia’s Fastest

Fastest 50 Bioscience Companies in Asia - 2012 (By % Growth)Rank Company Country Revenue

CY 2012Revenue CY 2011

Revenue CY 2010

Revenue CY 2009

Revenue CY 2008

% Growth over 2011

26 Sino Biopharmaceutical China 1082.80 751.92 525.88 425.24 306.74 44.00

27 Shandong Wohua Pharmaceutical China 33.54 23.81 13.43 25.20 28.15 40.85

28 SciVision Biotech Taiwan 6.02 4.30 - 0.47 0.18 39.89

29 Biota Holdings Australia 24.20 17.32 16.54 88.30 38.24 39.72

30 Dr Chip Biotechnology Taiwan 1.40 1.01 - 2.87 1.79 38.95

31 Ajanta Pharma India 153.17 111.04 97.07 75.36 65.63 37.94

32 Arvind Remedies India 119.09 86.47 77.04 55.84 42.68 37.72

33 Aarti Drugs India 161.29 118.22 107.77 94.98 128.40 36.44

34 Macrogen* South Korea 39.72 29.14 20.26 9.20 13.16 36.30

35 Neuren Pharmaceuticals Australia/New Zealand 4.50 3.31 4.80 3.94 2.04 35.95

36 Glenmark Pharmaceuticals India 383.94 282.71 260.14 205.67 221.62 35.81

37 Sihuan Pharmaceutical China 486.80 358.73 - - - 35.70

38 Lupin India 1395.47 1028.78 929.84 725.31 645.51 35.64

39 Fisher & Paykel Healthcare Australia 548.07 404.09 - - - 35.63

40 Aarey Drugs India 32.50 23.97 12.89 6.70 6.21 35.60

41 Heartware Australia 110.90 82.80 55.20 24.20 0.26 33.94

42 Celestial Biolabs India 5.11 3.82 5.37 5.16 3.54 33.72

43 Bloomage BioTechnology China 44.00 32.98 - - - 33.41

44 Adimmune Taiwan 11.62 8.71 - - - 33.35

45 Sagittarius Life Science Taiwan 11.34 8.53 - 8.94 1.34 32.89

46 Sinopharm China 21728.89 16355.97 10226.54 6884.09 5588.51 32.85

47 Granules India India 133.25 100.58 86.56 77.13 59.86 32.49

48 Seegene South Korea 46.30 35.46 - - - 30.57

49 Torrent Pharma India 513.62 394.20 380.20 286.65 300.22 30.29

50 Divis Laboratories India 437.81 336.99 257.41 201.34 238.85 29.92* Q4 Revenue extrapolated/estimated due to non-availability of data (Revenue in million $)

Companies

Fastest 50


Fastest 50

CEO & MD Dr Deborah Rathjen

Website: www.bionomics.com.au

Start-up Year: 1999

Bionomics is a drug candidate developer that focuses on unmet clinical needs. Bionomics’ pipeline includes BNC105, a vascular disrupting agent for the treatment of solid tumors, currently in Phase II clinical trials; BNC210, which is under development for the treatment of anxiety disorders; Kv1.3, which are blockers to treat inflammatory disorders; and Alpha 7 program for Alzheimer’s disease.

$13.80 mn

Reven

ue

2

Au

strA

liA

2Bionomics

General manager & director: Mr Ming Xin Pan

Website: www.huapont.com.cn

Start-up Year: 1992

Ch

inA

Huapont-Nutrichem is the fastest growing com-pany in active pharmaceutical ingredient manufacturing for generic markets in China and internationally. The company’s Active Pharma-ceutical Ingredient (API) products include retinoids, glucocorticoids, dermatology, oncology products. It has achieved Japan’s accreditation as foreign drug manufacturer for R&D in retinoic acids series prod-ucts, that accounts for over 56 percent market share in China.

Reven

ue

$618.30 mnHuapont-nutricHem 1

CEO: Mr Yee Pinh Jeremy

Website: www.cordlifeindiacom

Start-up Year: 2001

Cordlife, stem cell banking system from cord blood, is the first AABB-accredited private cord blood bank in Singa-pore and South East Asia. Cordlife has established cell banks with full processing and cryopreservation storage facilities in Singapore and Hong Kong, delivering services to over 7,200 families. Cord blood has the potential to provide treatment for diseases like blood cancers such as acute myelogenous leukaemia, and acute lymphoblastic leukemia.

$9.56 mn

Reven

ue

2

sin

gA

pore

4cordlife

CEO: Dr Keelung Hong

Website: www.tlcbio.com

Start-up Year: 1997

tAiw

An

The company focuses on innovative pharmaceuti-cal products based on its proprietary drug delivery technologies. Its strengths lie in lipid-based formulation parenteral drugs to optimize the pharmacokinetics of drugs for better efficacy and lower toxicity. Among other drug delivery technologies by the company is receptor-targeted immunoliposomes for antibody-mediated intracellular deliv-ery of therapeutics.

Reven

ue

$7. 22 mntaiwan liposome company 3

MD: Ms Andrea Grant

Website: www.lctglobal.com

Start-up Year: 1987

new

ZeA

lAn

d /

A

ust

rAli

A

It is the first company to enter clinical trials using therapeutic porcine cell implants globally. The company has developed Diabecell for people suffering from unstable Type 1 diabetes. Tiny Dia-becell microspheres, containing live islet cells, are implanted into a pa-tient’s abdomen using a simple laparoscopic procedure. Once implant-ed, Diabecell works by self-regulating and efficiently secreting insulin and glucagon in response to the patient’s changing glucose levels.

Reven

ue

$6.29 mnliving cell tecHnologies 5

486%

235%

208%

172%

154%

Bio

sp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3


Executive chairman: Mr Ross Dobinson BBus

Website: www.acrux.com.au

Start-up Year: 1992

Acrux provides pharmaceutical products using in-novative, patented technology to administer drugs through the skin. It has developed fast drying, non-occlusive topical sprays for an en-hanced transdermal delivery platform with low or no skin irritation, superior cosmetic acceptability, and simple, accurate and flexible dos-ing. Acrux earns revenue from its products through licensees in the global market.

$11.22 mn

Reven

ue

2

Au

strA

liA

7acrux

Chairman: Xu Wencai

Website: www.apeloa.com

Ch

inA

Apeloa Kangyu is engaged in R&D, manufactur-ing and marketing of APIs, formulations and veterinary drugs. It also supplies high quality chemical synthesis as well as biological synthe-sis products. Apeloa Kangyu owns two GMP certified and the US FDA approved facilities, and have passed OSHAS18001, ISO14001 and ISO9001 certifications. Nearly 50 percent of its products are sold to over 32 countries and regions in Asia, Europe and the US.

Reven

ue

$556.82 mnapeloa Kangyu 6

CEO: Mr Paul Wright

Website: www.universalbiosensors.com

Start-up Year: 2001

Universal Biosensors has developed OneTouch Verio blood glucose test strips, a blood glucose monitoring product commercialized globally by LifeScan, a Johnson & Johnson company. Using a tiny finger prick blood sample, OneTouch Verio enables in-stant readings of blood glucose levels. The company is now developing Prothrombin Time, a test to monitor the effect of the blood thinning anticoagulant warfarin, using its electrochemical cell technology.

$30.70 mn

Reven

ue

2

Au

strA

liA

9universal Biosensors

CEO & MD: Mr Ron Weinberger

Website: www.nanosonics.com.au

Start-up Year: 2001

Au

strA

liA

It has developed Trophon, a next generation ultra-sound probe disinfection system, to fight healthcare acquired infections (HAI). The technology produces a proprietary disinfectant containing sub-micron mist which can be quickly distributed to surfaces requir-ing disinfection or sterilization. The Center for Disease Control and Prevention estimates that as many as two million people suffer from HAIs annually in the US, resulting in more than 100,000 deaths.

Reven

ue

$12.68 mnnanosonics 8

General manager: Mr Xin De Yao

Website: www.layncorp.com

Start-up Year: 1995

Ch

inA

Guilin Layn Natural Ingredients is focused on identification, development and production of active principles derived from plants that are traditionally recognized as having therapeutic properties, with application in the food and beverage, nutrition, health and personal care industries. Layn has invested in new manufacturing facility with 16 state-of-the-art, fully computer controlled cGMP extrac-tion lines for a total capacity of 15,000MT raw material annually.

Reven

ue

$38.70 mn

guilin layn natural ingredients 10

127%

118%

112%

103%

95%

Fastest 50B

iosp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3


Fastest 50

CEO: Ms Alison J Mew

Website: www.gtglabs.com

Genetic Technologies, a genetic diagnostics com-pany with access to over 2000 different genetic tests, has developed BREVAGen, a test that looks for the presence (or absence) of genetic variations in women’s DNA known as Single Nucleotide Polymor-phisms, or SNPs. The test identifies changes in DNA to either confirm a diagnosis of a specific disorder of which a person displays signs or symptoms, or to identify individuals at risk of developing a disease.

$3.65 mn

Reven

ue

2

Au

strA

liA

12genetic tecHnologies

CEO: Mr Gary Phillips

Website: www.pharmaxis.com.au

Start-up Year: 1998

Au

strA

liA

Pharmaxis has developed Aridol, a drug designed to identify hyper-responsive airways and to assist in diagnosing and managing asthma. Aridol is approved for sale in Australia, major Eu-ropean countries, South Korea and the US. Pharmaxis’s another prod-uct Bronchitol is designed to restore normal lung hydration, improve lung function and help relieve the mucus burden in the lungs of pa-tients suffering from chronic respiratory conditions.

Reven

ue

$2.16 mnpHarmaxis 11

CEO: Mr Jung Hyun-Ho

Website: www.medytox.com

Start-up Year: 2000

Medy-Tox researches, develops and manufactures biopharmaceutical products using clostridium botulinum, a micro-organism toxin known as botox, widely used for treating ophthalmic diseases, endocrine diseases, digestive systems, neurological diseases, urology systems, and beauty treatments. Medytox has received Aus-tralia’s TGA approval in phase II clinical trial of next generation botu-linum toxin.

$32.50 mn

Reven

ue

2 14medy-tox

Chairman & president: Mr Zhu Chunlin

Website: www.ntjhzy.com/en

Start-up Year: 2002

Ch

inA

Nantong Jinghua Pharmaceutical is a dominant enterprise in pharmaceutical research, development and manufacture of APIs, intermediates, formulations, and traditional Chinese medi-cines. Main APIs by the company include Phenobarbital, Primidone, 5-Fluorouracil, 5-Flucytosine, Phenylbutazone, Piroxicam, Aminoglu-tethimide, Tenoxicam, Propylthiouracil, Moxonidine HCl and their intermediates and derivatives.

Reven

ue

$106.43 mn

nantong JingHua pHarmaceutical 13

CEO: Mr Ming Bo Xu

Website: www.slpharm.com.cn

Start-up Year: 1994

Ch

inA

Beijing SL Pharmaceutical develops and markets gene engineering drugs like Li Sheng Su, a recombinant human granu-locyte colony-stimulating factor for injection for treating neutropenia; Mai Ge Er, a recombinant human interleukin-11, for injection to treat thrombocytopenia; and Xin Ji Er, a recombinant human 125Ala in-terleukin-2, for injection for various indications such as renal cancer, melanoma, and malignant pleural effusion.

Reven

ue

$161.20 mnBeiJing sl pHarmaceutical 15

91%

77%

77%

66%

62%

Bio

sp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3so

uth

Ko

re

A


MD & CEO: Mr James McBrayer

Website: www.cyclopharm.com/au

Start-up Year: 1984

Radiopharmaceutical company Cyclopharm has developed Technegas technology that emits gas-like substance which is inhaled by the patient via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single pho-ton emission computed tomography camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

$11.10 mn

Reven

ue

2

Au

strA

liA

17cyclopHarm

Executive chairman: Mr Mark Balnaves

Website: www.austofix.com.au

Au

strA

liA

Austofix manufactures and designs medical devic-es and implants for the field of Orthopaedics - the surgical specializa-tion concerned with the musculoskeletal system. Austofix has devel-oped Tectona Hip Plate for hip fractures, Volar Radius Plate for use in the treatment for fractures of the distal radius, intramedullary nail for fixation of up to four part fractures of the proximal humerus, as well as fractures of the humeral shaft.

Reven

ue

$2 mnaustofix 16

CEO: Mr Yang Rongming

Website: www.gzmpc.com

Start-up Year: 1951

The company engages in a combination of sci-entific research and production of pharmaceuticals, and traditional Chinese medicines. The company has invested on technological inno-vation system and has launched post-doctoral research programs. It has its own research and development center for key pharmaceutical projects. Its products such as no sugar as well as low sugar herbal tea beverages have recorded greater increase in sales revenue in 2012.

$1316.60 mn

Reven

ue

2

Ch

inA

19guangzHou pHarmaceutical

CEO: Mr Mark Wong Tai Chun

Website: www.alliedoverseas.com.hk

Ch

inA

Allied Overseas provides elderly care services and distribution of medical equipment in Hong Kong. It offers specialized care programs to fit individual’s physical, social, psychological, and re-habilitation requirements; special treatments; and dementia and para-medical services, as well as infirmary services. It operates four elderly care homes and is involved in the distribution of medical equipment to hospitals, medical centers, and other healthcare facilities.

Reven

ue

$27. 17 mnallied overseas 18

CEO: Mr Qing Hui Lin

Website: www.altratene.com

Start-up Year: 2002

tAiw

An

Allied Biotech is one of the leading manufactur-ers of carotenoids, which are marketed worldwide under the name Altratene. Its products include Beta-carotene, a color pigment that is used to impart color to food, beverage, pharmaceutical, and cosmetic products; Beta-Apo-8’, red color, which is used as a food colorant; Co-enzyme Q10, a coenzyme located in the mitochondria throughout the body; and Lycopene, a physiological antioxidant.

Reven

ue

$16.10 mnallied BiotecH 20

61%

56%

56%

51%

51%

Fastest 50B

iosp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3


Fastest 50

CEO: Ms Jie Deng

Website: www.huahanbp.com.hk

Start-up Year: 1992

The company is engaged in research, develop-ment, production and distribution of a range of herbal-based gyneco-logical medicines and bio-pharmaceutical products. It primarily offers prescription drugs, including the Yeosure series of gynecological anti-inflammatory products, Camptothecine series of anti-tumor products like Paclitaxel Injection, Xinshenghua Keli, an endocrine product, and Cefadroxil Granules, an anti-inflammatory product for infants.

$224.25 mn

Reven

ue

2

Ch

inA

22Hua Han Bio-pHarmaceutical

CEO: Mr Jianyu Yang

Website: www.cmsholdings.com

Start-up Year: 2009

Ch

inA

Concord Medical Services owns and operates a network of radiotherapy and diagnostic imaging centers throughout China. It provides support to its network of radiotherapy and diagnos-tic imaging centers. Prior to setting up new centers, it also arranges training for medical professionals and invites experts from academic or professional institutions to provide guidance in latest radiotherapy treatments.

Reven

ue

$107. 54 mn

concord medical services 21

Chairman/President: Mr Sun Baowei

Website: www.lishengpharma.com

Start-up Year: 1951

Focusing primarily on manufacturing and market-ing chemical drugs in China, Tianjin Lisheng Pharmaceutical provides drugs for cardio and cerebral vascular systems, anti-infection drugs, and hormone drugs. It offers drugs in the form of tablets, hard cap-sules, pills, free-dry powder injections, and water injections, as well as raw drugs. Tianjin Lisheng exports its products to Japan, Australia, South Korea, Europe, the Americas, and the South East Asia.

$178.91 mn

Reven

ue

2

Ch

inA

24tianJin lisHeng pHarmaceutical

MD: Mr Lim Sung (eddie) Tie

Website: www.vitalifesciences.com

Start-up Year: 1947

Au

strA

liA

Pharmaceutical and healthcare company Vita Life Sciences is developing wide range of supplements, vitamins, minerals, meal replacement, sports nutrition, and herbals for men, women and children under brand name Herbs of Gold and VitaScience in Austra-lia, and VitaHealth, VitaLife and Pharma Direct in rest of Asia. Prod-ucts developed by the company comply with the respective countries’ rules and regulations such as the DCA, FDA and TGA.

Reven

ue

$37. 23 mnvita life sciences 23

MD: Mr Jia De Lai

Website: www.okbiotech.com

Start-up Year: 2005

tAiw

An

Being one of the leading manufacturers of glucose meters, OK Biotech is known to develop quick response, reliable and stable products for diabetes patients. It develops blood glucose moni-toring systems with its brand Okmeter. The leading products by this company include Optima, Match, Link and Direct blood glucose me-ters. OK Biotech products are distributed worldwide. OK Biotech also provides professional OEM/ODM/contract manufacturing services.

Reven

ue

$22 mn

oK BiotecH 25

49%

49%

48%

46%

45%

Bio

sp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3


President: Mr Zhang Ge

Website: www.wohua.cn

Start-up Year: 1959

The company is an industry leader in developing, producing and selling Chinese herbal medicines for cardio-cerebral diseases. The company’s primary products are Xinkeshu tablets and capsules for the treatment of coronary heart disease; Naoxueshu Oral Liquid, which promotes blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus; and Yu-andu granules to treat influenza.

$33.54 mn

Reven

ue

2

Ch

inA

27sHandong woHua pHarmaceutical

Chairman/Founder: Mr Tse Ping

Website: www.sinobiopharm.com

Start-up Year: 2000

Ch

inA

For over a decade, Sino Biopharmaceuticals has developed and marketed biopharmaceutical products for the medi-cal treatment of ophthalmia. The company also produces modernized Chinese medicine and chemical medicine for the treatment of liver diseases, cardiovascular and cerebrovascular diseases, geriatric and hepatitis. Sino Biopharmaceuticals is currently developing therapy drugs for cancer, analgesic and respiratory diseases.

Reven

ue

$1082.80 mnsino BiopHarmaceutical 26

CEO & MD: Peter Cook

Website: www.biotapharma.com

This company focuses on the discovery and devel-opment of anti-infective products to prevent and treat serious and po-tentially life-threatening infectious diseases. Biota has discovered two generations of neuraminidase inhibitors (NIs) that have been com-mercialized, the first of which is zanamivir, marketed worldwide as Relenza by GlaxoSmithKline.

$24.20 mn

Reven

ue

2

Au

strA

liA

29Biota

Chairman: Mr Kaicheng Han

Website: www.scivision.com.tw

Start-up Year: 2001

tAiw

An

Known as the only company in Taiwan to mass produce Hyaluronic Acid by fermentation biotechnology, SciVision Biotech uses a self-owned genetic transfer technique. The company has successfully developed a non-traditional microbial fermentation technique to produce medical grade Hyaluronic Acid (HA) with high quality and high safety. It manufactures and distributes hyaluronic acid medical equipment.

Reven

ue

$6.02 mnscivision BiotecH 28

CEO: Mr Shin-Hwan Wang

Website: www.biochipnet.com

Start-up Year: 1998

tAiw

An

Engaged primarily in research, development, manufacture and distribution of biological products and testing de-vices, Dr Chip Biotechnology also provides detection services, technol-ogy transfer, and consulting services. Dr Chip Biotechnology provides DNA/RNA sample preparation kits, polymersac chain reaction kits, rapid hybridization equipment, biochips, testing agents, biological preparations, as well as components of biological testing equipment.

Reven

ue

$1.40 mndr cHip BiotecHnology 30

44%

41%

40%

40%

39%

Fastest 50B

iosp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3


Fastest 50so

uth

Ko

re

A

CEO & MD: Mr B Arvind Shah

Website: www.arvindremedies.com

Start-up Year: 1988

The company manufactures and markets allopath-ic and ayurvedic pharmaceutical products for local as well as interna-tional markets. Increasing its production capacity, product categories, market share, advancements in R&D, market reach and global accep-tance, the company has managed to get a strong foothold in the Indian pharmaceutical industry. The company boasts of its ability to deliver both western and eastern varieties of quality treatments.

$119.09 mn

Reven

ue

2

ind

iA

32arvind remedies

Chairman: Mr Mannalal B Agrawal

Website: www.ajantapharma.com

Start-up Year: 1973

ind

iA

This Indian specialty pharmaceutical company is engaged in the development, manufacture and commercialization of pharmaceutical products. The company pioneers in synergistic com-bination products in the therapeutic areas of anti-malarial, cardiology, dermatology, gastroenterology, musculoskeletal, ophthalmology and re-spiratory. Its undivided focus on specialty segments in India and simul-taneous opening of new international markets have ensured its growth.

Reven

ue

$153.17 mnaJanta pHarma 31

CEO: Mr HyungTae, Kim

Website: www.macrogen.com

Start-up Year: 1997

Macrogen provides DNA sequencing and genome research services, and also raises and sells transgenic and knockout mice to biotechnology institutes and pharmaceutical companies. Mac-rogen develops DNA chips, which are used to improve the diagnosis and treatment of disease as well. Among other services, Macrogen of-fers sequencing services for base sequence analysis of plasmid and PCR product, 16S rDNA sequencing, and sequencing of DNA templates.

$39.72 mn

Reven

ue

2 34macrogen

CEO & MD: Mr Prakash M Patil

Website: www.aartidrugs.co.in

Start-up Year: 1984

ind

iA

Aarti Drugs has established a strong presence in the anti-diarrhea and anti-inflammatory therapeutic groups of drugs. It manufactures vitamins, anti-arthritis, anti-fungal, antibiotics, ACE inhibitors, along with anti-diabetic, anti-cholinergic, sedatives, and anti-depressant drugs. The company is also in the process of acquir-ing an ISO 9002 compliance for all its units and one of the units has already been approved.

Reven

ue

$161.29 mnaarti drugs 33

Executive chairman: Mr Richard Treagus

Website: www.neurenpharma.com

This dynamic biopharmaceutical company devel-ops human therapies for neuroprotection and metabolic related disor-ders. Its drugs target acute indications of brain injury such as traumat-ic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Neuren is also engaged in research and develop-ment in metabolic disorders such as cancers related to the functions of growth hormone.

Reven

ue

$4.50 mnneuren pHarmaceuticals 35

new

ZeA

lAn

d /

A

ust

rAli

A

38%

38%

36%

36%

36%

Bio

sp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3

siHuan pHarmaceutical company

sou

th K

or

eA

A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum �0

Chairman & CEO: Dr Che Fengsheng

Website: www.sihuanpharm.com

Start-up Year: 2001

In merely 11 years, this company has grown to be-come the ninth biggest pharmaceutical company in China’s prescrip-tion drug market. Sihuan is also the largest cardio-cerebral vascular prescription drug franchise by market share. The company’s product portfolio comprises proprietary products that encompass all the five medical therapeutic areas in China: cardio-cerebral vascular system, central nervous system, metabolism, oncology and anti-infectives.

$486.80 mn

Reven

ue

2

Ch

inA

37siHuan pHarmaceutical company

Chairman & MD: Mr Glenn Saldanha

Website: www.glenmarkpharma.com

Start-up Year: 2000

ind

iA

This company has significant presence in the branded generics markets across many emerging economies. It is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity), with five molecules in various stages of clinical development. Glenmark ranks among world’s top pharma and biotech companies, and has 13 manufacturing facilities in four countries and five R&D centers.

Reven

ue

$383.94 mn

glenmarK pHarmaceuticals 36

Chairman & director: Mr Michael G Daniell

Website: www.fphcare.com

Start-up Year: 1971

Fisher & Paykel manufactures, designs and mar-kets products and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnoea. It focuses on respiratory and acute care respiratory humidifiers, single-use and reusable cham-bers and breathing circuits, and sells its products in 120 countries. Its neonatal care products include infant warmers, infant resuscitators and CPAP systems to improve infant respiratory function.

$548.07 mn

Reven

ue

2

Au

strA

liA

39fisHer & payKel HealtHcare

Group President: Mr Shakti Chakraborty

Website: www.lupinworld.com

Start-up Year: 1968

ind

iA

Recognized for becoming one of the world’s largest manufacturers of tuberculosis drugs, the company today is the seventh largest Indian domestic formulations major in the Indian pharmaceu-tical market. Lupin boasts of holding a significant market share in key markets in the cardiovascular, diabetology, asthma, pediatrics, CNS, GI, anti-infectives and NSAIDs therapy segments along with being the global leaders in anti-TB and cephalosporins segments.

Reven

ue

$1395.47 mn

lupin 38

Chairman: Mr Jagdish K Shah

Website: www.aareydrugs.com

Start-up Year: 1990

ind

iA

Aarey Drugs is increasingly growing popular for being manufacturer representatives and suppliers of pharmaceutical raw materials, chemicals, pharmaceuticals ingredients, API drugs, and food colors and flavors. Currently, the company is working on the manufacturing of Metronidazole and Metronidazole Benzoate. The company is soon planning to introduce two new products and is diver-sifying in development of drug intermediates.

Reven

ue

$32.50 mnaarey drugs 40

36%

36%

36%

36%

36%

Fastest 50B

iosp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3

�� BioSpectrum | www.BioSpectrumAsia.com | A CyberMedia Publication

Fastest 50

MD & chairman: Dr Aditya narayan Singh

Website: www.celestiallabs.com

Start-up Year: 1997

The company has three decades of experience in drug discovery using Insilico process. Currently, the company is en-gaged in biopharmaceutical formulations, consisting of herbal, nutra-ceuticals and enzyme formulations. The company has prioritized the development of 4C Peptide through a biological route for the treat-ment of Vitiligo, tanning and ant wrinkles. It also plans to venture into the online marketing of natural products

$5.10 mn

Reven

ue

2

ind

iA

42celestial BiolaBs

CEO:

Mr Douglas Godshall

Website: www.heartware.com

Au

strA

liA

This medical devices company develops a family of implantable Left Ventricular Assist Devices (LVADs) for the treatment of advanced heart failure. It delivers safe, high performing and trans-formative therapies that enable patients with heart failure to get back to life. The company’s innovative technologies are creating advances in the miniaturization of Ventricular Assist Devices (VADs) leading to less invasive surgical procedures.

Reven

ue

$110.90 mn

Heartware 41

Chairman, president & CEO: Chan Chi-Hsien

Website: www.adimmune.com.tw

Start-up Year: 1965

With over 45 years of expertise in vaccinology, Ad-immune engages in the development, manufacture, and distribution of human vaccines in Taiwan. The company’s primary products include seasonal influenza vaccine, AdimFlu-s (A/H1N1), Japanese encephali-tis vaccine, and tetanus toxoid alum precipitated, as well as tuberculin purified protein derivative for mantoux testing. Currently, it is looking at preparing a vaccine for H7N9 avian influenza.

$11.62 mn

Reven

ue

2

tAiw

An

44adimmune

Chairman: Mr Zhao Yan

Website: www.bloomagebio-tech.com

Start-up Year: 2006

Ch

inA

Abiding by the company’s motto ‘Open stream delivers excellence’, the company has become the market leader in producing hyaluronic acid (HA) that is used in medical, cosmetic, and food products. HA, the key product of this company, is a kind of gly-cosaminoglycans used mainly in pharmaceutical products, cosmetics and health supplement. The US, Japan, the European Union, Canada, Brazil, Korea and Taiwan are its leading markets.

Reven

ue

$44 mnBloomage BiotecHnology 43

Chairman/President: Mr Chen Le-Wei

Website: www.sagittarius.com.tw

Start-up Year: 1998

tAiw

An

The company develops a wide range of Chinese herbal medicines and supplements. The company’s products include SO101C, an anti-ageing agent for the prevention and treatment of bone fractures and osteoporosis; ST104P, an anti-angiogenesis agent; ST188L, the immune booster; SA201D, a transdermal patch for Al-zheimer’s disease; SA103T, an anti-osteoarthritis agent; and SS102T, a wound healing and skin care agent.

Reven

ue

$11.34 mnsagittarius life science 45

Bio

sp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3 34%

34%

33%

33%

33%

A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum ��

Chairman: Dr C nageswara Rao

Website: www.granulesindia.com

Start-up Year: 1984

Granules India manufactures Finished Dosages (Fds), Pharmaceutical Formulation Intermediates (PFIs) and APIs that are distributed across 50 countries. The company also manufac-tures several off-patent drugs, including Paracetamol, Ibuprofen, Met-formin and Guaifenesin, on a large scale for customers in the regulated and semi-regulated markets. Granules exports mainly to developed markets like the US, Europe, Mexico and Hong Kong.

$133.25 mn

Reven

ue

2

ind

iA

47granules india

Board Chairman: Mr She Lulin

Website: www.sinopharm.com

Start-up Year: 1998

Ch

inA

With operations in Africa, France, Germany, Hong Kong, the US and Vietnam, today Sinopharm is China’s largest phar-maceutical company. It is jointly owned by China National Pharmaceu-tical and Shanghai Fosun Pharmaceutical. The company researches, develops, manufactures, distributes, and markets medicine and other healthcare products through its three main segments - pharmaceutical distribution, retail pharmacy, and other business.

Reven

ue

$21.17 bn

sinopHarm 46

Chairman: Mr Sudhir Mehta

Website: www.torrentpharma.com

Start-up Year: 1970

The company focuses on formulations, API, drug discovery, marketing and sales of drugs. Torrent has dominated the market of therapeutic areas of cardiovascular (CV) and central ner-vous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments. Torrent Pharma, through its subsidiaries, plans to make an entry into several regulated and less regulated international markets.

$513.62 mn

Reven

ue

2

ind

iA

49torrent pHarma

CEO: Jong-Yoon Cheon

Website: www.seegene.com

Start-up Year: 2000

This company specializes in molecular diagnos-tics and develops technology and products that diagnose disease from the genetic level. So far, the company has various molecular diagno-sis products that are developed in-house including simultaneous and multiple detection technologies (Acp, Dpo, Read, Toce). Seegene’s in-novate technology allows testing of multiple pathogens with one single test, thereby minimizing testing time and cost.

Reven

ue

$46.30 mnseegene 48

Chairman & MD: Mr Murali K Divi

Website: www.divislabs.com

Start-up Year: 1990

ind

iA

The company was established to primarily con-duct research and development of new processes for the production of APIs and intermediates. Soon the company expanded to provide com-plete turnkey solutions to the Indian pharmaceutical industry. Divis is involved in developing alternate, patent non-infringing processes for APIs, for the inventors to manage late life cycle and leading generic drug manufacturers.

Reven

ue

$437. 81 mndivis laBoratories 50

Bio

sp

ectru

m a

sia

fa

ste

st 5

0 l

ist 2

01

3so

uth

Ko

re

A

33%

32%

30%

30%

30%

Fastest 50

Asia Top 20 Survey Fastest 50 Bioscience Companies in Asia

Documents

Transcript of Asia Top 20 Survey Fastest 50 Bioscience Companies in Asia